These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 6237086

  • 1. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF, Bleehen NM, Workman P.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [Abstract] [Full Text] [Related]

  • 3. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Hirst VK, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
    Workman P, Ward R, Maughan TS, Newman HF, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):177-81. PubMed ID: 2526107
    [Abstract] [Full Text] [Related]

  • 13. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
    Bleehen NM, Newman HF, Maughan TS, Workman P.
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
    Newman HF, Bleehen NM, Workman P.
    Br J Radiol; 1986 Apr; 59(700):423-5. PubMed ID: 2938660
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The hypoxic cell sensitizer programme in the United States.
    Phillips TL, Wasserman TH, JohnsonRJ, Gomer CJ, Lawrence GA, Levine ML, Sadee W, Penta JS, Rubin DJ.
    Br J Cancer Suppl; 1978 Jun; 3():276-80. PubMed ID: 277245
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.